Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Total Valuation
Corvus Pharmaceuticals has a market cap or net worth of $203.04M. The enterprise value is $314.81M.
Market Cap$203.04M
Enterprise Value$314.81M
Share Statistics
Corvus Pharmaceuticals has 68.14M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68.14M
Owned by Insiders34.59%
Owned by Instutions43.70%
Financial Efficiency
Corvus Pharmaceuticals’s return on equity (ROE) is -1.91 and return on invested capital (ROIC) is -81.77%.
Return on Equity (ROE)-191.27%
Return on Assets (ROA)-90.40%
Return on Invested Capital (ROIC)-81.77%
Return on Capital Employed (ROCE)-82.22%
Revenue Per Employee$0
Profits Per Employee-$2,009,451.613
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corvus Pharmaceuticals is -5.24. Corvus Pharmaceuticals’s PEG ratio is -0.06.
PE Ratio-5.24
PS Ratio0.00
PB Ratio10.02
Price to Fair Value10.02
Price to FCF-12.83
Price to Operating Cash Flow-12.83
PEG Ratio-0.06
Income Statement
In the last 12 months, Corvus Pharmaceuticals had revenue of $0.00 and earned -$62.29M in profits. Earnings per share was -$0.99.
Revenue$0.00
Gross Profit-$44.00K
Operating Income-$27.55M
Pretax Income-$62.29M
Net Income-$62.29M
EBITDA-27.46M
Earnings Per Share (EPS)-0.99
Cash Flow
In the last 12 months, operating cash flow was -$25.42M and capital expenditures $0.00, giving a free cash flow of -$25.42M billion.
Operating Cash Flow-$25.42M
Free Cash Flow-$25.42M
Free Cash Flow per Share-$0.37
Dividends & Yields
Corvus Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-7.79%
Earnings Yield-19.09%
Stock Price Statistics
Beta1.54
52-Week Price Change102.72%
50-Day Moving Average4.17
200-Day Moving Average5.11
Relative Strength Index (RSI)33.09
Average Volume (3m)728.86K
Important Dates
Corvus Pharmaceuticals upcoming earnings date is May 1, 2025, After Close.
Last Earnings DateMar 25, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Corvus Pharmaceuticals as a current ratio of 1.54, with Debt / Equity ratio of 0.03
Current Ratio1.54
Quick Ratio1.54
Debt to Market Cap<0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio-15.10
Taxes
In the past 12 months, Corvus Pharmaceuticals has paid -$20.28K in taxes.
Income Tax-$20.28K
Effective Tax Rate0.00%
Enterprise Valuation
Corvus Pharmaceuticals EV to EBITDA ratio is -11.57, with an EV/FCF ratio of -12.53.
EV to Sales0.00
EV to EBITDA-11.57
EV to Free Cash Flow-12.53
EV to Operating Cash Flow-12.53
Balance Sheet
Corvus Pharmaceuticals has $51.96M in cash and marketable securities with $1.12M in debt, giving a net cash position of -$50.84M billion.
Cash & Marketable Securities$51.96M
Total Debt$1.12M
Net Cash-$50.84M
Net Cash Per Share-$0.75
Tangible Book Value Per Share$0.53
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corvus Pharmaceuticals is $13.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.00
Price Target Upside336.24%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast-71.53%